Track topics on Twitter Track topics that are important to you
Cambrex Corporation (NYSE:CBM) provides products and services to accelerate the development and commercialization of branded and generic small molecule therapeutics. Cambrex supports its customers worldwide with R&D and cGMP manufacturing facilities in the US and Europe, an excellent regulatory compliance record and strong expertise in various chemical technologies. Pharmaceutical Products & Services Cambrex has built a comprehensive platform of chemical technologies for the synthesis of small molecule active pharmaceutical ingredients (APIs). We have extensive experience developing drug substances from early stage through clinical development, up to launch and commercial supply – from grams to tons. Cambrex has a broad range of services, which include: route selection, process development, analytical development, process scale-up, safety assessments and optimization. Our core technologies and offerings include: Highly Potent & Cytotoxic Compounds, High Energy, Hydrogenation, Biocatalysis/Biotransformation, Chiral Synthesis, Controlled Substances, Nitration and Polymeric Drug Delivery, including Taste Masking. Generic APIs For generic drug companies, Cambrex supplies more than 70 APIs (including controlled substances) for pain management, cardiovascular, gastrointestinal, central nervous system, endocrine and respiratory indications. Cambrex manufactures these products using complex chemistry and technical expertise while maintaining its long-standing reputation of quality and reliability. We work with generic drug companies well in advance of drug patent expiration, provide a non-infringing process and file a Drug Master File (DMF) for the generic active pharmaceutical ingredients.
ONE MEADOWLANDS PLAZA,
United States of America
Phone: 201 804 3000
EAST RUTHERFORD, N.J., Feb. 6, 2012 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased to announce that Greg Sargen, Executive Vice President and Chief Financial Officer, will ...
Cambrex Corporation is investing $24m in a new facility to manufacture highly potent APIs (HPAPIs).
Cambrex Corporation is installing a fourth reactor suite at its High Point, NC-based facility as it continues to grow with its customers in the market, says company VP at CPhI North America.
Cambrex Corporation has increased new capacity at its Sweden-based cGMP as the manufacturer focuses on market demand and customer need, says VP.
Cambrex Corporation says higher demand for APIs for controlled substances and branded drugs drove Q2 growth and confirms it is on the lookout for acquisitions.
Cambrex, manufacturer of small molecule active pharmaceutical ingredients (APIs), has announced it is investing in new capacity and continuous flow technology at its Karlskoga facility in Sweden.
NewsCambrex invests to increase pilot scale API capacity at its High Point, NC facility.Contributed Author:
Cambrex Corporation is adding a new $3.2m, 11,000 square foot analytical laboratory to its High Point, NC-based facility.
Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including APIs, advanced intermediates, enhanced drug delivery, and other prod...
Cambrex Corporation (NYSE:CBM) provides products and services to accelerate the development and commercialization of branded and generic small molecule therapeutics. Cambrex supports its customers wor...
We have published hundreds of Cambrex news stories on BioPortfolio along with dozens of Cambrex Clinical Trials and PubMed Articles about Cambrex for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambrex Companies in our database. You can also find out about relevant Cambrex Drugs and Medications on this site too.
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...